← SynDRA
REMOGLIFLOZIN ETABONATE
SynDRA canonical compound SYN0029187 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | SLC5A2 |
|---|
| Mechanism of action | sodium/glucose cotransporter inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
Mechanisms of action (all sources)
- SLC5A2 INHIBITOR
- Sodium/glucose cotransporter 2 inhibitor
- sodium/glucose cotransporter inhibitor
- SLC5A4 BLOCKER
Drug classes
- Sodium-Glucose Transporter 2 Inhibitors
Cross-references
Synonyms
- Etabonate de remogliflozine
- Etabonato de remogliflozina
- Gsk189075
- BHV-091009
- GSK-189075
- GSK-189075A
- GSK189075A
- KGT-1681
- GSK 189075
- GSK 189075A
- TR0QT6QSUL
- GSK189075
- remogliflozini etabonas
- RefChem:879227
- DTXCID501390958
- Remogliflozin etabonate [INN]
- UNII-TR0QT6QSUL
- Remogliflozin etabonate [USAN]
- S0993
- SCHEMBL721678
- orb1695501
- CHEBI:177541
- UAOCLDQAQNNEAX-ABMICEGHSA-N
- C26H38N2O9
- GLXC-24226
- Remogliflozin etabonate (USAN/INN)
- BDBM50559516
- MFCD17167013
- MSK177665
- AKOS030528241
- Remogliflozin etabonate (GSK189075)
- REMOGLIFLOZIN ETABONATE [WHO-DD]
- BR162756
- DA-77400
- HY-14945
- MS-29684
- CS-0003650
- NS00069708
Look up REMOGLIFLOZIN ETABONATE in the interactive SynDRA portal →